2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
HIV Infections
2
Sarcoma, Kaposi
1
Lymphoma, AIDS-Related
1
Dendritic Cell Sarcoma, Interdigitating
1
Acquired Immunodeficiency Syndrome
1
Interventions
Etoposide
9
Rituximab
8
Cyclophosphamide
7
Vincristine
6
Prednisone
6
Doxorubicin
5
Filgrastim
4
Cytarabine
3
Radiotherapy
2
Procarbazine
2
Peripheral Blood Stem Cell Transplantation
2
Melphalan
2
Lomustine
2
Carmustine
2
prednylidene
1
pegylated granulocyte colony-stimulating factor
1
pegfilgrastim
1
liposomal doxorubicin
1
ibrutinib
1
ibritumomab tiuxetan
1
etoposide phosphate
1
efavirenz
1
deltacortene
1
VAP-cyclo protocol
1
Ultrasonography
1
Radioimmunotherapy
1
Ondansetron
1
O(6)-benzylguanine
1
Mitoguazone
1
Methylprednisolone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, AIDS-Related
×
Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination
×
Clear all
NCT00799136
2013-09-12
CATCH
Ontario Clinical Oncology Group (OCOG)
Phase 2
Completed
6 enrolled